Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 24, 2025Annals of HematologyOpen Access

Developmental stage modulates the prognostic impact of RAS pathway mutations in AML patients undergoing Allo-HSCT

View Full Paper
Ask AI
Bookmark
Share

Authors

XYXiaolin YuanYWYibo WuYWYanan Wang

Discussion

Loading...

Member takes

Overview

Randomized trial shows developmental stage affects prognosis of AML with RAS mutations post-allo-HSCT, implying tailored approaches may be needed.

Key Points

  • This study investigates how RAS pathway mutations and developmental stages affect the prognosis of AML patients after allo-HSCT.
  • Enrolled 364 adult AML patients undergoing first allo-HSCT with myeloablative conditioning
  • Analyzed the cumulative incidence of relapse, overall survival, and leukemia-free survival as primary and secondary endpoints
  • Conducted subgroup analyses based on the developmental stage of AML patients (primitive vs. monocytic)
  • Patients with RAS-pathway mutations in the primitive subgroup had a higher cumulative incidence of relapse (CIR) of 38.6% vs. 14.8%, P = 0.016
  • In the monocytic subgroup, RAS-pathway mutations correlated with a lower CIR of 3.4% vs. 26.8%, P = 0.013 and improved leukemia-free survival (LFS) of 93.1% vs. 66.9%, P = 0.013
  • Hazard ratio for higher CIR in the primitive subgroup was HR = 2.55 (95% CI: 1.21-5.40) while for improved LFS in the monocytic subgroup, HR = 0.23 (95% CI: 0.06-0.96)

Cite This Study

Yuan et al. (2025) studied this question.

synapsesocial.com/papers/6a0752db85d51e7cc7584b25https://doi.org/10.1007/s00277-025-06694-3
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clearance of RAS pathway mutations prior to allogeneic transplant in Acute Myeloid Leukemia are associated with favorable overall and leukemia free survival2025 · 1 citations
  2. 2Impact of NRAS and/or KRAS mutations on post-transplant outcomes in Acute Myeloid Leukemia: A study on behalf of EBMT-ALWP2025
  3. 3Clinico-genomic characterization of RAS-mutant acute myeloid leukemia2026 · 2 citations
  4. 4Clinical significance of RAS-MAPK pathway mutations in Acute Myeloid Leukemia: Insights from a retrospective cohort2025
  5. 5Clinical implications of RAS mutations in AML: Prognostic significance is based upon involved gene and mutation complexity2026